Investor Relations

Investor Overview

KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.950.000.00%0
Previous CloseToday's OpenIntraday HighIntraday Low
$3.95$0.00$4.05$3.85
Exchange: NASDAQ (US Dollar)
12/07/16 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
11/29/16
KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
11/09/16
KemPharm, Inc. Reports Third Quarter 2016 Results
11/03/16
KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources